Literature DB >> 3263229

Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies.

M Massaia1, U Dianzani, A Bianchi, A Camponi, M Boccadoro, A Pileri.   

Abstract

The generation of cytotoxic T lymphocytes (CTL) towards allogeneic cells was investigated in 19 patients with monoclonal gammopathy of undetermined significance (MGUS) and 31 patients with multiple myeloma (MM). This function was significantly decreased in all patients. The cytotoxic deficiency was more pronounced in MM with poor prognosis than MM with good prognosis and MGUS patients. A phenotypic analysis of PBT lymphocytes showed that poor prognosis MM also had the highest proportions of activated cells (HLA-DR+) in CD8+ subpopulations. CTL were generated after depletion of CD11+ lymphocytes (including suppressor cells) or after inhibition of suppressor function with deoxyguanosine. No increase of cytotoxicity was detected under these conditions. Exogenous supplementation of recombinant interleukin 2 (rIL-2) was also ineffective. These data indicate that MG PBT lymphocytes are unable to fully differentiate into CTL following allogeneic stimulation. This deficiency is most evident in MM patients already showing the poorest prognosis and the most altered T cell phenotype.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263229      PMCID: PMC1541589     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  Multiple myeloma: ecto-5' nucleotidase deficiency of suppressor/cytotoxic (CD8) lymphocytes is a marker for the expansion of suppressor T cells.

Authors:  M Massaia; U Dianzani; P Pioppo; E Sibilla; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

Review 2.  Immunoregulatory circuits in myeloma.

Authors:  S Ullrich; S Zolla-Pazner
Journal:  Clin Haematol       Date:  1982-02

3.  Enhanced T cell suppression is directed toward sensitive circulating B cells in multiple myeloma.

Authors:  R T Perri; M M Oken; N E Kay
Journal:  J Lab Clin Med       Date:  1982-04

4.  The cellular basis for viral-induced immunodeficiency: analysis by monoclonal antibodies.

Authors:  E L Reinherz; C O'Brien; P Rosenthal; S F Schlossman
Journal:  J Immunol       Date:  1980-09       Impact factor: 5.422

5.  Metabolic properties of IgG subclasses in man.

Authors:  A Morell; W D Terry; T A Waldmann
Journal:  J Clin Invest       Date:  1970-04       Impact factor: 14.808

6.  Multiple myeloma: an immunologic profile. Cytotoxic and suppressive effects of the EA rosette-forming cell.

Authors:  T Paglieroni; M R Mackenzie
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

7.  Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone.

Authors:  M O Dailey; E Pillemer; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

8.  Inhibition of suppressor T-cell development following deoxyguanosine administration.

Authors:  H M Dosch; A Mansour; A Cohen; A Shore; E W Gelfand
Journal:  Nature       Date:  1980-06-12       Impact factor: 49.962

9.  Functional activity in vivo of effector T cell populations. I. Antitumor activity exhibited by allogeneic mixed leukocyte culture cells.

Authors:  H D Engers; G D Sorenson; G Terres; C Horvath; K T Brunner
Journal:  J Immunol       Date:  1982-09       Impact factor: 5.422

10.  T cells in monoclonal gammopathies.

Authors:  H Mellstedt; G Holm; D Pettersson; M Björkholm; B Johansson; C Lindemalm; D Peest; A Ahre
Journal:  Scand J Haematol       Date:  1982-07
View more
  8 in total

1.  Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies.

Authors:  M Massaia; A Bianchi; U Dianzani; A Camponi; C Attisano; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

2.  Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma.

Authors:  Vito Racanelli; Patrizia Leone; Maria Antonia Frassanito; Claudia Brunetti; Federico Perosa; Soldano Ferrone; Franco Dammacco
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

Review 3.  Immune checkpoint blockade for hematologic malignancies: a review.

Authors:  Matthew J Pianko; Yuzhou Liu; Srishti Bagchi; Alexander M Lesokhin
Journal:  Stem Cell Investig       Date:  2017-04-19

4.  A disturbance of the IL-2/IL-2 receptor system parallels the activity of multiple myeloma.

Authors:  A Vacca; R Di Stefano; A Frassanito; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

5.  Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.

Authors:  Larry D Anderson; Danielle R Cook; Tori N Yamamoto; Carolina Berger; David G Maloney; Stanley R Riddell
Journal:  Cancer Immunol Immunother       Date:  2011-04-03       Impact factor: 6.968

Review 6.  Immune senescence in multiple myeloma-a role for mitochondrial dysfunction?

Authors:  Frances Seymour; Jonathan Carmichael; Claire Taylor; Christopher Parrish; Gordon Cook
Journal:  Leukemia       Date:  2022-07-25       Impact factor: 12.883

Review 7.  Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.

Authors:  Alessandro Allegra; Vanessa Innao; Andrea Gaetano Allegra; Marta Pugliese; Eleonora Di Salvo; Elvira Ventura-Spagnolo; Caterina Musolino; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2019-06-10       Impact factor: 5.923

8.  Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.

Authors:  B C Millar; J B Bell; R L Powles
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.